France
SynapCell is a biotechnology company founded in 2005, specializing in drug efficacy evaluation at the preclinical stage using EEG-based methods. Their innovative approach provides drug developers with quantitative and unbiased endpoints through longitudinal monitoring of drug effects on translational models, mirroring clinical protocols.
The company excels in various capabilities including dose-response studies, pharmacodynamics, and biomarker identification, with a strong focus on Neuroscience fields like Epilepsy, Parkinson's disease, and Schizophrenia. This has positioned them uniquely within the Biotechnology, Health Care, and Pharmaceutical industries.
With its headquarters in the United States, SynapCell benefits from returning customers across major markets in the USA, Japan, Korea, and Europe. The company's reputation is bolstered by a strategic $4.43M Series A investment from partners such as Grenoble Angels and VIADUC 8. This robust foundation suggests strong potential for continued success and growth.
